Understanding how Azacitidine resistance develops in certain blood cancers
Characterization of the Mechanisms of Action of Resistance to Azacitidine in High-risk Myelodysplastic Syndromes and Acute Myeloid Leukemia With Multilineage Dysplasia
This study looks at how some patients with high-risk blood cancers stop responding to the treatment Azacitidine to help find better ways to fight these diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 4 sites (Antibes and 3 other locations) |
| Trial ID | NCT01210274 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize the molecular mechanisms of resistance to Azacitidine in patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with multilineage dysplasia. It focuses on understanding how Azacitidine, a treatment known for its DNA demethylation effects, influences cell death programs such as apoptosis and autophagy in leukemic cells. By analyzing patients who have undergone multiple cycles of Azacitidine, the study seeks to uncover the biological factors that contribute to treatment resistance. This research could provide insights into improving therapeutic strategies for these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with high-risk or intermediate 2 MDS or AML with multilineage dysplasia who have received at least three to six cycles of Azacitidine.
Not a fit: Patients who have received other chemotherapies or those with lower-risk MDS may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to enhanced treatment strategies for patients with high-risk MDS and AML, potentially improving their outcomes.
How similar studies have performed: While the mechanisms of Azacitidine have been explored, this specific focus on resistance mechanisms is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * High Risk or Intermediate 2 MDS (IPSS) * AML-MD (WHO classification) * Treatment with minimum three to six cycles of Azacitidine * Informed consent form signed Exclusion Criteria: * Treatment with others chemotherapies alone or in association
Where this trial is running
Antibes and 3 other locations
- CH d'Antibes — Antibes, France (Recruiting)
- CHU de Nice - Hôpital de l'Archet — Nice, France (Recruiting)
- Centre Antoine Lacassagne — Nice, France (Recruiting)
- CH Princesse Grace — Monaco, Monaco (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.